Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00806156
Recruitment Status : Completed
First Posted : December 10, 2008
Last Update Posted : August 15, 2014
Information provided by (Responsible Party):
Nektar Therapeutics

Brief Summary:

This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced platinum-resistant ovarian cancer.

Approximately 70 patients will be randomized 1:1 into one of two treatment arms. NKTR-102 will be administered at a dose level of 145 mg/m2 in both arms. In Arm A, NKTR-102 will be given on a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. After the initial 70 patients have been enrolled, Arm B will enroll approximately 110 additional patients.

Condition or disease Intervention/treatment Phase
Tumor Ovarian Cancer Drug: NKTR-102 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 178 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Study Start Date : October 2008
Actual Primary Completion Date : October 2012
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Drug: NKTR-102
NKTR-102 given on a q14 day schedule
Experimental: 2
Drug: NKTR-102
NKTR-102 given on a q21 day schedule

Primary Outcome Measures :
  1. Objective Response Rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
  2. Inoperable metastatic or locally advanced ovarian cancer
  3. Platinum-resistant ovarian cancer defined as progression by RECIST within 6 months of last dose of most recent platinum drug
  4. Platinum-resistant patients who have progressed after receiving PLD (Doxil/Caelyx)therapy in a platinum-resistant setting or who otherwise unable to receive PLD therapy.
  5. Diseases must be measurable as defined by RECIST in at least 1 lesion not previously irradiated.
  6. ECOG performance score of 0 or 1.
  7. Adequate organ and bone marrow functions at Screening.

Exclusion Criteria:

  1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) and have not recovered to NCI-CTCAE grade 1 toxicity prior to Day 1 of Cycle 1
  2. Patients who have had any major surgery within 4 weeks prior to Day 1 of Cycle 1 or minor surgery within 2 weeks prior to Day 1 of Cycle 1
  3. Patients who have received CYP3A4 inducers or inhibitors.
  4. Patients who have received any treatment with a camptothecin derivative (eg. irinotecan, topotecan, SN38 investigational agents, etc.).
  5. Patients with CNS metastases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00806156

United States, California
Beaver Medical Group
Highland, California, United States, 92346
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Gynecologic Oncology Associates
Newport Beach, California, United States, 92663
United States, Florida
Palm Beach Cancer Center
West Palm Beach, Florida, United States, 33401
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Michigan
Sparrow Regional Cancer Center
Lansing, Michigan, United States, 48912
United States, North Carolina
Piedmont Hematology Oncology Associates
Winston-Salem, North Carolina, United States, 27103
United States, Oklahoma
Surgical Gynecological Associates
Oklahoma City, Oklahoma, United States, 73142
United States, Rhode Island
Pharma Resource
East Providence, Rhode Island, United States, 02915
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
UZ Gent
Gent, Belgium
UZ Leuven
Leuven, Belgium
CHU de Liege
Liege, Belgium
GasthuisZusters Antwerpen
Wilrijk, Belgium
United Kingdom
Mount Vernon Hospital
Middlesex, Northwood, United Kingdom
University Hospital Coventry
Coventry, United Kingdom
Ninewells Hospital
Dundee, United Kingdom, DD1 9SY
Beastson Oncology Centre
Glasgow, United Kingdom, G12 OYN
Freeman Hospital
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Sponsors and Collaborators
Nektar Therapeutics
Study Director: Ivan Gergel, MD Nektar Therapeutics

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nektar Therapeutics Identifier: NCT00806156     History of Changes
Other Study ID Numbers: 08-PIR-04
First Posted: December 10, 2008    Key Record Dates
Last Update Posted: August 15, 2014
Last Verified: August 2014

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders